
Keywords: PAHs; Polycyclic aromatic hydrocarbons; CVD; Cardiovascular disease; T2DM; Type 2 diabetes mellitus; PM; Particulate matter; MetS; Metabolic syndrome; OH-PAHs; Monohydroxy urinary metabolites of PAHs; HOMA2; Updated Homeostasis Model Assessment; NHANES; N